噻托溴铵联合布地奈德福莫特罗粉吸入剂治疗重度支气管哮喘并AECOPD的效果
|
摘要
目的分析噻托溴铵与布地奈德福莫特罗粉吸入剂治疗重度支气管哮喘并慢性阻塞性肺病急性加重期(AECOPD)的临床价值。方法回顾性分析73例重度支气管哮喘并AECOPD患者的临床资料,其中采用基础治疗+噻托溴铵+布地奈德福莫特罗粉吸入剂的有37例,记为A组;使用基础治疗+噻托溴铵的有36例,记为B组。比较两组用药前、后的肺功能指标、临床疗效及不良反应发生情况。结果用药后,两组FVC、FEV1、PEF水平均升高,且A组明显高于B组(P<0.05)。A组患者的治疗总有效率明显高于B组(P<0.05)。两组患者的不良反应总发生率比较,差异不显著(P>0.05)。结论噻托溴铵联合布地奈德福莫特罗粉吸入剂治疗重度支气管哮喘并AECOPD能改善患者的肺功能,提升治疗效果,且不会显著增加不良反应。
Objective To analyze the clinical value of tiotropium bromide combined with budesonide and formoterol fumarate powder for inhalation on severe bronchial asthma complicated with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Methods The clinical data of 73 patients with severe bronchial asthma and AECOPD were retrospectively analyzed. Thirty-seven patients were treated with basic therapy +tiotropium bromide +budesonide and formoterol fumarate powder for inhalation, which was recorded as group A. Thirty-six patients were treated with basic therapy +tiotropium bromide, which was recorded as group B. The lung function indexes before and after medication,curative effects and adverse reactions of the two groups were compared. Results After medication, the levels of FVC, FEV1 and PEF increased in both groups, and those of the group A were significantly higher than the group B(P<0.05). The total effective rate of treatment in the group A was significantly higher than that in the group B(P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Budesonide and formoterol fumarate powder for inhalation in the treatment of severe bronchial asthma complicated with AECOPD can improve patients' lung function and therapeutic effect, which will not significantly increase adverse reactions.
Objective To analyze the clinical value of tiotropium bromide combined with budesonide and formoterol fumarate powder for inhalation on severe bronchial asthma complicated with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Methods The clinical data of 73 patients with severe bronchial asthma and AECOPD were retrospectively analyzed. Thirty-seven patients were treated with basic therapy +tiotropium bromide +budesonide and formoterol fumarate powder for inhalation, which was recorded as group A. Thirty-six patients were treated with basic therapy +tiotropium bromide, which was recorded as group B. The lung function indexes before and after medication,curative effects and adverse reactions of the two groups were compared. Results After medication, the levels of FVC, FEV1 and PEF increased in both groups, and those of the group A were significantly higher than the group B(P<0.05). The total effective rate of treatment in the group A was significantly higher than that in the group B(P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Budesonide and formoterol fumarate powder for inhalation in the treatment of severe bronchial asthma complicated with AECOPD can improve patients' lung function and therapeutic effect, which will not significantly increase adverse reactions.
引文
[1]李德鹏.无创正压通气在COPD急性加重期呼吸衰竭治疗中的作用[J].海南医学院学报,2016,22(9):892-894.
[2]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675-697.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-80.
[4]罗慰慈.现代呼吸病学[M].北京:人民军医出版社,1997:80-81.
[5]方荣,王倩,冯丽伟,等.IL-13、TNF-α在慢性阻塞性肺疾病和哮喘患者中的检测意义[J].临床肺科杂志,2016,21(8):1410-1412.
[6]王臣,谭明旗.噻托溴铵联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的临床疗效[J].实用药物与临床,2016,19(5):573-576.
[2]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675-697.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-80.
[4]罗慰慈.现代呼吸病学[M].北京:人民军医出版社,1997:80-81.
[5]方荣,王倩,冯丽伟,等.IL-13、TNF-α在慢性阻塞性肺疾病和哮喘患者中的检测意义[J].临床肺科杂志,2016,21(8):1410-1412.
[6]王臣,谭明旗.噻托溴铵联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的临床疗效[J].实用药物与临床,2016,19(5):573-576.